The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Open accessAbstract
Purpose: Our preclinical work identified depletion of ATR as a top candidate for topoisomerase 1 (TOP1) inhibitor synthetic lethality and showed that ATR inhibition sensitizes tumors to TOP1 inhibitors. We hypothesized that a combination of selective ATR inhibitor M6620 (previously VX-970) and topotecan, a selective TOP1 inhibitor, would be tolerable and active, particularly in tumors with high replicative stress. Patients and Methods: This phase I study tested the combination of M6620 and topotecan in 3-week cycles using 3 + 3 dose escalation. The primary end point was the identification of the maximum tolerated dose of the combination. Efficacy and pharmacodynamics were secondary end points. Results: Between September 2016 and February 2017, 21 patients enrolled. The combination was well tolerated, which allowed for dose escalation to the highest planned dose level (topotecan 1.25 mg/m 2 , days 1 to 5; M6620 210 mg/m 2 , days 2 and 5). One of six patients at this dose level experienced grade 4 thrombocytopenia that required transfusion, a dose-limiting toxicity. Most common treatment-related grade 3 or 4 toxicities were anemia, leukopenia, and neutropenia (19% each); lymphopenia (14%); and thrombocytopenia (10%). Two partial responses (≥ 18 months, ≥ 7 months) and seven stable disease responses ≥ 3 months (median, 9 months; range, 3 to 12 months) were seen. Three of five patients with small-cell lung cancer, all of whom had platinum-refractory disease, had a partial response or prolonged stable disease (10, ≥ 6, and ≥ 7 months). Pharmacodynamic studies showed preliminary evidence of ATR inhibition and enhanced DNA double-stranded breaks in response to the combination. Conclusion: To our knowledge, this report is the first of an ATR inhibitor-chemotherapy combination. The maximum dose of topotecan plus M6620 is tolerable. The combination seems particularly active in platinum-refractory small-cell lung cancer, which tends not to respond to topotecan alone. Phase II studies with biomarker evaluation are ongoing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Causes and consequences of replication stress
Zeman, M. K., & Cimprich, K. A. (2014) · Nature Cell Biology · doi:10.1038/ncb2897 · Cited by 2,079
Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses
Rothkamm, K., & Löbrich, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830918100 · Cited by 1,645
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J.-D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.573 · Cited by 633
Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., & Fernandez-Capetillo, O. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2076 · Cited by 465
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13837 · Cited by 382
Cited by
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Lecona, E., & Fernandez-Capetillo, O. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 325
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence
Duy, C., Li, M., Teater, M., Meydan, C., Garrett-Bakelman, F. E., Lee, T. C., Chin, C. R., Durmaz, C., Kawabata, K. C., Dhimolea, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1375 · Cited by 253
Metadata
- Authors
- Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., Tran, L., Yutzy, W., Rajan, A., Guha, U., Chen, H., Hassan, R., Alewine, C. C., Szabo, E., Bates, S. E., Kinders, R. J., Steinberg, S. M., Doroshow, J. H., Aladjem, M. I., Trepel, J. B., & Pommier, Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-06-01
- Volume
- 36
- Issue
- 16
- Pages
- 1594-1602
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2775990711
- Cited by
- 171
- References
- 7
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.2017.76.6915
- The paper
- Thomas, A., Redon, C. E., Sciuto, L., Padiernos, E., Ji, J., Lee, M.-J., Yuno, A., Lee, S., Zhang, Y., Tran, L., Yutzy, W., Rajan, A., Guha, U., Chen, H., Hassan, R., Alewine, C. C., Szabo, E., Bates, S. E., Kinders, R. J., . . . Pommier, Y. (2018). Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.76.6915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.